3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
6
Phase 1/2
3
Phase 3
2
Phase 4
1
Phase 1
1
Status
Completed
2
Sponsor Class
OTHER
1
INDUSTRY
1
Study Type
Interventional
2
Sponsor
Cancer Type
CNS
1
Conditions
Breast Neoplasms
298
Carcinoma, Non-Small-Cell Lung
225
Neoplasms
155
Prostatic Neoplasms
154
Multiple Myeloma
116
Neoplasm Metastasis
83
Colorectal Neoplasms
80
Leukemia, Myeloid, Acute
74
Lung Neoplasms
71
Parkinson Disease 4, Autosomal Dominant Lewy Body
68
Melanoma
67
Leukemia, Lymphocytic, Chronic, B-Cell
63
Lymphoma, Follicular
62
Lymphoma, Non-Hodgkin
61
Papillomavirus Infections
59
Leukemia
59
Pain
52
Lymphoma
52
Uterine Cervical Neoplasms
50
Precursor Cell Lymphoblastic Leukemia-Lymphoma
49
Ovarian Neoplasms
47
Carcinoma, Hepatocellular
46
Keratosis, Actinic
44
Carcinoma, Renal Cell
44
Recurrence
43
Head and Neck Neoplasms
43
Stomach Neoplasms
38
Lymphoma, Large B-Cell, Diffuse
34
Urinary Bladder Neoplasms
33
Squamous Cell Carcinoma of Head and Neck
32
Interventions
Sirolimus
1
Everolimus
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Phase 3
×
Has results
×
Lymphangioleiomyomatosis
×
Clear all
NCT00414648
2023-11-02
MILES
University of Cincinnati
Phase 3
Completed
89 enrolled
15 charts
NCT00790400
2017-02-17
EXIST-2
Novartis
Phase 3
Completed
118 enrolled
15 charts